PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

Current Oncology Reports
Lise WillemsDidier Bouscary

Abstract

The mammalian target of rapamycin (mTOR) and the phosphoinositide 3-kinase (PI3K) signaling pathways are commonly deregulated in cancers and promote cellular growth, proliferation, and survival. mTOR is part of two complexes, mTORC1 and mTORC2, with different biochemical structures and substrates specificity. PI3K/AKT activation may result from genetic hits affecting different components of the pathway, whereas the mechanisms leading to constitutive mTORC1 activation remain globally unknown. The connections between the PI3K and mTOR kinases are multiple and complex, including common substrates, negative feedback loops, or direct activation mechanisms. First-generation allosteric mTOR inhibitors (eg, rapamycin) are mainly active on mTORC1 and mostly display cytostatic anti-tumor activity. Recently, second-generation catalytic mTOR inhibitors targeting both mTOR complexes 1 and 2 have been developed. Some of them also inhibit class IA PI3K. Here, we highlight recent data generated with these new inhibitors against cancer cells and their potential as anti-cancer drugs.

References

Mar 19, 2004·Nature·Hans-Guido WendelScott W Lowe
Feb 19, 2005·Science·D D SarbassovDavid M Sabatini
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Apr 11, 2006·Molecular Cell·Dos D SarbassovDavid M Sabatini
Aug 17, 2006·Blood·Ludivine LeseuxChristine Bezombes
Sep 6, 2006·British Journal of Cancer·R T KurmashevaP J Houghton
Dec 7, 2007·Blood·Cédric Dos SantosChristian Récher
Aug 30, 2008·The Journal of Clinical Investigation·Arkaitz CarracedoPier Paolo Pandolfi
Sep 17, 2008·Oncogene·T L Yuan, L C Cantley
Jan 20, 2009·The Journal of Biological Chemistry·Carson C ThoreenNathanael S Gray
Feb 13, 2009·PLoS Biology·Morris E FeldmanKevan M Shokat
May 1, 2009·The Biochemical Journal·Juan M García-MartínezDario R Alessi
Jul 25, 2009·Nature Reviews. Cancer·Jeffrey A Engelman
Aug 1, 2009·Nature Reviews. Drug Discovery·Pixu LiuJean J Zhao
Jan 15, 2010·Nature Medicine·Matthew R JanesDavid A Fruman
Mar 18, 2010·Nature Reviews. Clinical Oncology·Janet Dancey
Jul 29, 2010·The Journal of Clinical Investigation·Federica Di NicolantonioAlberto Bardelli
Sep 10, 2010·Science Translational Medicine·Jeffrey J WallinLori S Friedman
Oct 5, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicolas ChapuisDidier Bouscary
Nov 5, 2010·The Journal of Investigative Dermatology·Johannes WerzowaVolker Wacheck
Nov 11, 2010·Science Signaling·Qi-Wen FanWilliam A Weiss
Dec 16, 2010·Nature Reviews. Molecular Cell Biology·Roberto ZoncuDavid M Sabatini
Mar 3, 2011·Nature Reviews. Clinical Oncology·Sarah P Blagden, Anne E Willis
Mar 8, 2011·Cell·Vittoria ZinzallaMichael N Hall
Mar 15, 2011·Expert Opinion on Investigational Drugs·Daniel W Bowles, Antonio Jimeno
Mar 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jessica K AltmanLeonidas C Platanias
Apr 16, 2011·Leukemia·L S SteelmanJ A McCubrey

❮ Previous
Next ❯

Citations

Dec 29, 2012·Molecular Cancer Therapeutics·Stefan HartJeanette M Wood
Apr 17, 2013·BMC Veterinary Research·Lorella ManiscalcoRaffaella De Maria
Apr 5, 2013·World Journal of Gastroenterology : WJG·Lin-Feng XuYu-Dan Wu
Oct 25, 2014·Lung Cancer Management·Haiying ChengRoman Perez-Soler
Apr 17, 2014·Pathology Oncology Research : POR·Tímea PóczaPéter Hauser
Oct 27, 2015·Biomolecules·Chara Stavraka, Sarah Blagden
Aug 10, 2012·Expert Opinion on Pharmacotherapy·Georg FeldmannPeter Brossart
Jul 9, 2014·Cancers·Tasuku Matsuoka, Masakazu Yashiro
Oct 9, 2013·Expert Opinion on Investigational Drugs·Håkon ReikvamJerome Tamburini
Jan 15, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Byron K Y BitanihirweIsabelle Opitz
Jul 23, 2013·Human Pathology·Henning ReisHideo-Andreas Baba
Jun 5, 2013·Translational Oncology·Thomas J HaymanPhilip J Tofilon
May 31, 2015·Biochimica Et Biophysica Acta·Casey L KohnhorstSongon An
Aug 14, 2012·Advances in Biological Regulation·L BracciniE Hirsch
Jan 18, 2016·Bioorganic & Medicinal Chemistry Letters·Wooseok HanSabina Pecchi
Aug 8, 2015·Respirology : Official Journal of the Asian Pacific Society of Respirology·Maria Eleni VazakidouIoannis Kalomenidis
Dec 21, 2012·Chemical Biology & Drug Design·Joseph J Provost, Mark A Wallert
Feb 11, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N-Y Chia, P Tan
May 2, 2014·British Journal of Pharmacology·M MoschettaM R Carratù
Sep 17, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xiaofeng BaiDongbing Zhao
Jun 12, 2013·Veterinary and Comparative Oncology·J S FowlesD L Gustafson
Jun 25, 2015·Carcinogenesis·Kannan Badri NarayananHyun Ho Park
Jun 13, 2013·Expert Opinion on Therapeutic Targets·Camilla EvangelistiAlberto M Martelli
Feb 28, 2015·Brain : a Journal of Neurology·Laura A JansenWilliam B Dobyns
Jan 28, 2015·International Journal of Oncology·Kamran HaratiAdrien Daigeler
Aug 15, 2014·Archives of Gynecology and Obstetrics·Jens C HahneArnd Honig
Oct 27, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·R Pinto-LeiteL Santos

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

© 2022 Meta ULC. All rights reserved